Last edition
News about Global Pharma
Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the world’s first PD-1 inhibitor approved for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the Indian market.
Global Pharma | 06/08/2025 | By Mrinmoy Dey | 441
Polpharma Biologics, Fresenius Kabi Partners to Commercialise A Proposed Vedolizumab Biosimilar
Polpharma Biologics, a European biotechnology company, has entered into a global licensing agreement with German multinational healthcare firm Fresenius Kabi for the commercialisation of PB016—a proposed biosimilar to vedolizumab.
Global Pharma | 06/08/2025 | By Dineshwori | 329
Governor of New York State Kathy Hochul has announced that Garonit Pharmaceutical, a global manufacturer of antiseptic products and health care solutions, will establish a state-of-the-art, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County.
Global Pharma | 05/08/2025 | By Dineshwori | 379
Viatris Appoints David Simmons to the Company's Board of Directors
Viatris Inc. has appointed seasoned pharma executive David Simmons to its Board of Directors, bringing decades of global leadership, R&D, and capital markets experience to support the company’s strategic growth.
Global Pharma | 05/08/2025 | By Mrinmoy Dey | 249
Laborate Pharmaceuticals Achieves EU-GMP Certification for Paonta Sahib Manufacturing Facility
Laborate Pharmaceuticals has announced that its state-of-the-art manufacturing facility in Paonta Sahib, Himachal Pradesh, has been awarded the EU-GMP (European Union - Good Manufacturing Practice) certification by the relevant European regulatory authority.
Global Pharma | 05/08/2025 | By Dineshwori | 753
US Tariffs on EU Pharma Imports Threaten Drug Access and Innovation, GlobalData Warns
The US-EU trade deal has placed the pharmaceutical industry under significant fiscal strain, with consequences that extend beyond short-term financials, according to GlobalData, a leading data and analytics company.
Global Pharma | 05/08/2025 | By Dineshwori | 287
Everest Medicines to Invest USD 30.9 Million in I-MAB
Everest Medicines has announced a strategic equity investment of USD 30.9 million in US-based biotech firm I-Mab, strengthening its position in next-generation oncology and enhancing synergies across global markets.
Global Pharma | 04/08/2025 | By Mrinmoy Dey | 174
Alveolus Bio Secures Strategic Investment from Shilpa Medicare
Alveolus Bio has announced a strategic financing round led by Shilpa Medicare, which will also serve as its exclusive global development and manufacturing partner to accelerate clinical advancement of its inhaled biotherapeutics for respiratory diseases.
Global Pharma | 04/08/2025 | By Mrinmoy Dey | 199
Moderna Sees 41 Percent Q2 Revenue Drop as COVID Vaccine Sales Decline
Moderna posted USD 142 million in revenue for the second quarter 2025, down 41 percent from USD 241 million in the same period last year.
Global Pharma | 04/08/2025 | By Dineshwori | 288
Aurobindo Pharma USA To Acquire Lannett For USD 250 Million, Enter ADHD Treatment Space
Aurobindo Pharma USA Inc., has entered into a definitive agreement to acquire 100 percent membership interest in Lannett Company LLC from its parent company, Lannett Seller Holdco, Inc.
Global Pharma | 31/07/2025 | By Dineshwori | 596
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy